Advertisement
CCR Focus

Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer

Mario Sznol and Lieping Chen
DOI: 10.1158/1078-0432.CCR-12-2063 Published March 2013

Abstract

The immune suppressive molecule programmed death-1 (PD-1) is upregulated in activated T lymphocytes and inhibits T-cell function upon binding to its ligands B7-H1 (PD-L1, CD274) and B7-DC (PD-L2, CD273). Substantial experimental data from in vitro cell culture systems and animal models, and more recently from clinical trials, indicate that PD-1/PD-1-ligand interactions are a major mechanism of immune suppression within the tumor microenvironment. Initial clinical studies of antibodies directed against PD-1 and B7-H1 showed both an encouraging safety profile and remarkable antitumor activity in subsets of patients with metastatic disease, including malignancies—such as lung cancer—which were previously thought to be unresponsive to immunotherapy. Preliminary data have suggested a correlation between tumor membrane B7-H1 expression and clinical response to anti-PD-1 antibodies. Several key challenges remain to optimize development of PD-1/B7-H1 pathway blockade, including defining the biologic significance of all potential ligand–receptor interactions in the tumor microenvironment, developing more accurate predictive biomarkers of response, determining the breadth of activity in human malignancies, and developing rational combinations of therapy that address key mechanisms involved in positive and negative regulation of antitumor immune responses. Clin Cancer Res; 19(5); 1021–34. ©2013 AACR.

Introduction

Antigen-specific T-cell responses are controlled positively and negatively by costimulatory and coinhibitory molecules, respectively. Coinhibitory molecule signaling prevents inappropriately directed immunity and limits the size and duration of immune responses. Among the key coinhibitory molecules, broadly categorized as “checkpoint molecules,” are CTL antigen-4 (CTLA-4), which controls early stages of T-cell activation, and programmed death-1 (PD-1; ref. 1). PD-1 (CD279) is a member of the B7-CD28 family that regulates T-cell activation, peripheral tolerance, and the prevention of bystander tissue damage during immune responses (2–4).

Induction and Expression of PD-1 and Its Counter-Receptors

PD-1, so named for its involvement in classical programmed cell death (1), is expressed on activated CD4+ and CD8+ T cells, natural killer (NK) T cells, B cells, and activated monocytes and dendritic cells (DC; ref. 4). PD-1 protein is not detectable on resting T cells but is found on the cell surface within 24 hours of T-cell activation (4). The known counter-receptors of PD-1, B7-H1 (also called PD-L1; ref. 5) and B7-DC (also called PD-L2; ref. 6)—both of which have been observed on cancer cells (7, 8)—have distinct expression profiles. Low levels of B7-H1 mRNA are found in virtually all normal tissues and cell types examined thus far (7). However, constitutive expression of B7-H1 cell-surface protein in normal tissues is rare and has been found [via immunohistochemistry (IHC)-based analysis] only in a fraction of tissue macrophages within lung, liver, tonsil, and placenta (9). These findings indicate the existence of 1 or more posttranscriptional mechanisms controlling B7-H1 cell-surface protein expression.

The biologic consequences of B7-H1 expression depend on cell membrane localization because it is presumed that B7-H1 is functional only when it ligates a counter-receptor. B7-H1 cell-surface protein can be induced by various inflammatory mediators, including IFN-α, -β, and -γ, bacterial lipopolysaccharide, granulocyte-macrophage colony-stimulating factor, VEGF, and the cytokines interleukin-4 (IL-4) and IL-10 (9–12). In particular, the IFN family of cytokines are potent inducers of B7-H1 mRNA and protein on cultured B7-H1− cells. In addition to binding PD-1, B7-H1 can also bind CD80 on activated T cells, thus inhibiting T-cell activation and production of cytokines (4).

B7-DC is expressed on myeloid dendritic cells, activated T cells, and some nonhematopoietic tissues (including lung; ref. 6), although only on a minority of patient tumors (6, 8, 13–15). Further studies are required to define the role of B7-DC expression, induction, and signaling on T-cell activation and function. Results from studies of B7-DC-knockout mice and in vitro studies have been inconsistent and show either increased or decreased response to antigens (14–16). These results are consistent with an as-yet unrecognized second receptor for B7-DC. Several studies in the literature have provided evidence for a preferential inhibitory role of B7-DC on Th2 responses (17), which in addition to the known binding between B7-H1 and CD80, could explain potential differences in clinical activity and toxicity of antibodies targeted against B7-H1 versus those directed against PD-1.

Role(s) of the PD-1/B7-H1 Pathway in Healthy Hosts

In a healthy host, PD-1 signaling in T cells regulates immune responses to minimize damage to bystander tissue and prevents the development of autoimmunity by promoting tolerance to self-antigens. Ligation of PD-1 results in the formation of PD-1/T-cell receptor (TCR) inhibitory microclusters that recruit SHP2 molecules, which dephosphorylate multiple members of the TCR signaling pathway, effectively turning off T-cell activation (18). Inhibition of RAS and PI3K/AKT pathways was also shown, resulting in downstream suppression of cell-cycle progression and T-cell activation (ref. 19; Fig. 1). PD-1 ligation by B7-H1 on macrophages, other antigen-presenting cells (APC), or endothelium inhibits production of several cytokines, including IFN-γ, IL-2 (which protects against T-cell apoptosis), and TNF-α (4, 13), and promotes T-cell apoptosis via inhibition of survival factor Bcl-xL (4).

Figure 1.
Figure 1.

PD-1 signaling in inflamed tissue. Ligation of T-cell PD-1 by B7-H1 on APC leads to the formation of PD-1/TCR microclusters and the subsequent recruitment of SHP2 phosphatases, which dephosphorylate multiple members of the TCR signaling pathway. This abrogates downstream effects of T-cell activation, including cytokine production, cell-cycle progression, and the expression of survival proteins. By preventing T-cell activation, PD-1 signaling contributes to the maintenance of tolerance to self-antigens and prevents immune-mediated damage of healthy tissue during the resolution of infection and other inflammatory responses.

B7-H1 can also serve as a receptor. It has been shown that reverse signaling through B7-H1 in T cells and dendritic cells regulates cytokine production and inhibits dendritic cell maturation and survival of activated T cells (20, 21). B7-H1 signaling also inhibits tumor cell apoptosis induced by antigen-specific CD8+ T cells and in response to various stimuli (22). During chronic viral infection, B7-H1 expression in hematopoietic cells reduces the induction and functionality of virus-specific T-cell responses, whereas B7-H1 expressed in the nonhematopoietic compartment regulates tissue immunopathology and viral clearance (23). Thus, the functional consequences of B7-H1 interaction with its receptors are determined by the location of its expression.

Although PD-1 and its counter-receptors primarily control the function of effector cells, this pathway may also have a role in modulating T-cell priming (24). The varied regulatory roles of PD-1 signaling are supported by preclinical studies showing spontaneous, late-onset development of autoimmune disease in PD-1–deficient mice (25, 26). B7-H1–deficient mice do not display spontaneous autoimmunity (3, 27) but have increased T-cell accumulation in select peripheral organs and impaired apoptosis of CD8+ T cells (27). Several reports also suggest that PD-1/B7-H1 signaling contributes to regulatory T cell (Treg) induction, maintenance, and suppressive function (28) via the downregulation of mTOR and AKT phosphorylation (29).

Preclinical Studies of PD-1/B7-H1 Blockade in Antitumor Therapy

Multiple in vivo mouse experiments showed tumor regression or prolonged host survival after abrogation of PD-1 pathway signaling alone (9, 30, 31) or in combination with other agents, including cancer vaccines (32–37). Tumor regression was accompanied by increased effector T-cell (Teff) function and cytokine production. However, the exact sequence of events within the tumor microenvironment that culminates in tumor regression after PD-1 pathway blockade is unknown. Although it is reasonable to assume that PD-1 pathway blockade reactivates PD-1–expressing tumor-infiltrating lymphocytes (TIL; Fig. 2), studies of T-cell function in chronic viral infection suggest that the population of T cells expressing high levels of PD-1 are “exhausted” and may not be reactivated with PD-1 blockade alone (38). Exhausted T cells result from chronic antigen exposure (caused by persistent viral infections or progressive tumor), express high levels of inhibitory molecules, have poor effector functionality and a distinct transcriptional profile, and may, in fact, constitute a discrete stage of T-cell differentiation. In patients with metastatic melanoma (mMEL), CD8+ TIL can express several cell-surface molecules associated with exhaustion including TIM-3, LAG-3, and PD-1 (with some cells expressing all markers), which may be the cause of resistance to PD-1 pathway blockade in some patients and may provide the rationale for future combinations of checkpoint/coinhibitory molecule antagonists (39, 40). Recently, Mkrtichyan and colleagues reported that treating mice with a B7-DC-Ig fusion protein in combination with cyclophosphamide and a vaccine resulted in a significant decrease (via effects on B7-DC/PD-1 signaling and cell proliferation) in the number of PD-1hi CD4+ and CD8+ T cells within the tumor, allowing infiltration by and/or expansion of nonexhausted PD-1lo T cells into the tumor microenvironment (41). Whether this phenomenon occurs in human patients as a result of administration of the other PD-1 pathway-targeted immunotherapies presented later also remains to be determined.

Figure 2.
Figure 2.

PD-1 and cancer. A, ligation of T-cell PD-1 by tumor B7-H1 results in the downregulation of T-cell effector functions that destroy tumor tissue. B, blockade of this pathway by anti-PD-1 antibodies prevents this downregulation, and allows T cells to maintain their antitumor functionality and ability to mediate tumor cell death.

Expression and Prognostic Significance of PD-1, B7-H1, and B7-DC in Human Cancer

B7-H1 is expressed by various tumor tissues and high PD-1 expression is often present on TILs. Peripheral blood CD4+ and CD8+ T cells in patients with cancer can also express PD-1, in some cases in a large percentage of cells, which makes it unlikely that PD-1+ T cells exclusively represent tumor-specific T cells (42). These findings are consistent with recent data showing that PD-1 can be upregulated by common γ-chain cytokines including IL-2, IL-7, IL-15, and IL-21 (43).

Table 1 summarizes PD-1, B7-H1, and B7-DC expression in several different malignancies and correlates expression with patient prognosis. Most large retrospective studies show that B7-H1 expression correlates with poor prognosis and/or more aggressive disease; however, several reports indicate a lack of association (44–46) or even that B7-H1 expression is associated with improved survival and influx of lymphocytes into the tumor microenvironment (47). Although there may be biologic reasons to explain the discrepant outcomes, reviews of the literature correlating B7-H1 expression with prognosis should nevertheless be interpreted with caution, because of the heterogeneity in expression within tumor tissue, the requirement to assess membrane B7-H1 protein rather than intracellular protein or mRNA, the lack of specificity of several commercially available antibodies, and the substantial difficulty in developing reagents and methods for detection of B7-H1 expression in formalin-fixed, paraffin-embedded tissue (FFPE). B7-H1 protein contains only 2 small linear hydrophilic regions, and therefore, a limited number of antibody-binding sites (5). Because FFPE tumor tissue is generally available in patients with metastatic cancer but frozen tissue is not, a customized protocol was subsequently developed to renature B7-H1 in FFPE tissues (47, 48) permitting reproducible and specific immunohistochemical staining of B7-H1 with the 5H1 monoclonal antibody (mAb; ref. 9).

View this table:
Table 1.

PD-1, B7-H1, and B7-DC expression and prognostic significance in cancer patients

Thus far, only a small number of studies have examined the prognostic significance of B7-DC expression on tumor tissue and other cells within the tumor microenvironment. Tumor-cell B7-DC seems to be a negative predictor of survival for patients with esophageal carcinoma (49); other studies have identified either no relationship (50) or a correlative trend (although not significant) between B7-DC expression and reduced survival (51, 52). It should be noted that in many of these studies, B7-DC was expressed by only a minority of patient tumors (8).

Clinical Development of Antibodies Targeting the PD-1/B7-H1 Pathway

In human ex vivo studies of CD4+ or CD8+ T-cell activation, addition of an anti-B7-H1 or anti-PD-1 antibody augmented T-cell expansion and proliferation, increased cytokine production, and enhanced cytolytic activity (9, 53–55; Fig. 2). These data supported the clinical development of human antibodies blocking either PD-1 or B7-H1, several of which are currently being evaluated in clinical trials.

Nivolumab (MDX-1106, BMS-936558), a fully human monoclonal immunoglobulin (Ig)G4 antibody that binds PD-1 with high affinity and blocks its interaction with both B7-H1 and B7-DC, was initially evaluated in a standard phase I dose-escalation trial in which patients received intravenous doses from 0.3 to 10 mg/kg (56). Patients could be retreated with up to 2 courses, each course consisting of 2 doses spaced 4 weeks apart, at 12-week intervals. Among 39 patients, including 21 treated at 10 mg/kg, treatment produced a complete response (CR) lasting more than 21 months in a patient with colorectal cancer, partial responses in a patient with melanoma and a patient with renal cancer, and mixed responses in a patient with lung cancer and a patient with melanoma. PD-1 receptor occupancy was maintained beyond 60 days at all dose levels and beyond the time when drug levels were no longer detectable in the blood. In a subsequent, much larger phase I trial accruing 304 patients (as of July 2012), nivolumab was administered in doses ranging from 0.1 to 10 mg/kg i.v. every 2 weeks (57, 58). Small expansion cohorts were accrued in metastatic renal cell carcinoma (mRCC), melanoma, non–small cell lung carcinoma (NSCLC), prostate, and colorectal cancers. Including all dose levels, at the time of data analysis, objective responses were observed in 33 of 106 (31%), 20 of 122 (16%), and 10 of 34 (29%) of previously treated patients with mMEL, NSCLC, and mRCC, respectively. In NSCLC, objective response rate (ORR) and progression-free survival (PFS) rate at 24 weeks appeared higher at the 3- and 10-mg/kg dose levels compared with 1 mg/kg, but there was no clear dose–response relationship for activity in other diseases or for toxicity across the trial. No objective responses were observed in patients with prostate or colorectal cancer. Objective responses were durable (>6 months) in the majority of patients and several with sufficient follow-up remain progression-free even beyond 2 years. Thirteen patients showed nonconventional patterns of tumor response (such as prolonged reduction of tumor burden in the presence of new lesions) that were suggestive of clinical benefit but were not included in the calculation of ORR.

Nivolumab was well tolerated at all dose levels. Common drug-related adverse events included pruritus, rash, diarrhea, fatigue, nausea, and decreased appetite. Only 14% of the patients developed grade 3 or 4 drug-related adverse events. Pneumonitis was observed in 3% of all patients and 3 (2 NSCLC and 1 RCC; 1%) died from grade 3 or 4 pneumonitis-related events, leading to more proactive implementation of an early identification and intervention protocol including monitoring and administration of glucocorticoids. Gastrointestinal and hepatic adverse events were managed with treatment interruption or corticosteroids as necessary and endocrine adverse events were managed with replacement therapy, similar to the algorithms developed for management of ipilimumab immune-related adverse events. In a subset of 42 patients in which pretreatment paraffin-embedded tumor tissue was assessed for B7-H1 expression using the 5H1 antibody, no patients with B7-H1− tumors experienced an objective response, whereas 9 of 25 (36%) patients with B7-H1+ tumors (defined as ≥5% membrane expression) had an objective response (P = 0.006). Although these data support a role for tumor cell B7-H1 expression as a potential predictive biomarker of response to PD-1 pathway blockade, further confirmation will be required in larger patient populations.

Two other PD-1 antagonist antibodies are currently being evaluated in clinical trials. MK-3475, a humanized IgG4 with high affinity for PD-1, was well tolerated in doses ranging from 1 to 10 mg/kg administered i.v. 4 weeks apart and subsequently every 2 weeks (59). IL-2 production from ex vivo stimulated lymphocytes was increased at all 3 dose levels. No grade ≥3 drug-related adverse events were observed, although 1 patient developed pneumonitis-requiring corticosteroids. For the 13 patients with melanoma treated in the dose-escalation phase and 10-mg/kg expansion cohort, 7 confirmed or unconfirmed objective responses were observed. One of 4 patients with NSCLC also achieved a partial response (unconfirmed at the time of the presentation). Cohorts of patients with melanoma were subsequently treated at 10 mg/kg i.v. every 2 to 3 weeks or 2 mg/kg every 3 weeks (60). Among 83 evaluable patients at the time of presentation, including 25 previously treated with ipilimumab, the ORR was 47% and 40% in patients with prior ipilimumab therapy. Although follow-up was relatively short, responses were ongoing in most patients. The latter data confirmed the high rate of activity in mMEL observed with nivolumab and also showed substantial activity of anti-PD-1 even in patients with prior exposure to another checkpoint inhibitor (anti-CTLA-4). It remains unclear if the higher reported rates of response for MK-3475 are due to differences in patient selection or the antibody characteristics.

Another anti-PD-1 mAb, CT-011, is a humanized IgG1 antibody shown to enhance human NK and T-cell function in vitro. In a phase I trial in advanced hematologic malignancies examining doses from 0.2 to 6 mg/kg, only 1 patient experienced drug-related adverse events, and antitumor activity was observed in 1 patient with follicular lymphoma and 1 patient with acute myelogenous leukemia (AML; ref. 61). Development of CT-011 has been focused primarily in hematopoietic malignancies and in combination with select chemotherapies, although a large, single-agent phase II trial is being conducted in patients with mMEL. In addition, a phase I trial of a third PD-1 antagonist, the B7-DC-Fc fusion protein AMP-224, is ongoing.

Other antibodies blocking B7-H1 are also in clinical development. BMS-936559, a high-affinity human IgG4 that blocks B7-H1 binding to PD-1 and CD80, was evaluated at doses ranging from 0.3 to 10 mg/kg administered i.v. every 2 weeks (62). Among the 207 enrolled patients with advanced cancer, only 9% developed grade 3 or 4 treatment-related adverse events, similar to those observed with nivolumab. Across all dose levels and expanded cohorts, objective responses were observed in 9 of 52 (17%) patients with mMEL, 2 of 17 (12%) with mRCC, 5 of 49 (10%) with NSCLC, and 1 of 17 (6%) with ovarian cancer. A subset of responses was durable. Although the activity of this drug seems to be less than that observed with nivolumab, sample sizes were smaller and the patient populations were heterogeneous. It is also possible that lower response rates were caused by differences in the antibodies administered or in the functions of their molecular targets. Data from the phase I trial of anti-B7-H1 antibody MPDL3280A/RG7446 are not yet publicly available. Recently, Medimmune, the Ludwig Institute for Cancer Research (New York, NY), and the Cancer Research Institute (New York, NY) announced a partnership to pursue development of multiple anticancer immunotherapies, including the anti-B7-H1 mAb MEDI4736 (63). Table 2 presents ongoing trials with PD-1 pathway-targeted agents.

View this table:
Table 2.

Ongoing trials with PD-1 pathway-targeted immunotherapy

Perspectives and Future Directions

The promising clinical data available for agents blocking PD-1 and B7-H1 validate the PD-1/B7-H1 pathway as a critical anticancer and immunotherapy target and extend the potential for immunotherapy activity beyond melanoma and RCC to other solid tumors. ORRs in melanoma, RCC, and NSCLC for the anti-PD-1 antibody nivolumab and in melanoma for MK-3475 were sufficiently high to pursue registration trials as a single agent and phase I to III trials of more traditional empiric combinations with other approved chemotherapy or targeted agents. In the absence of definitive predictive biomarkers or clear understanding of tumor–host immune relationships in most malignancies (including the role of B7-DC), the activity observed to date may merit empiric phase II exploration of PD-1 pathway blockade in multiple types of solid tumors. Preclinical data showing the expression of PD-1 on B- and T-cell lymphomas, the role of B7-H1/B7-DC in blunting graft-versus-leukemia effect in a murine model of chronic phase chronic myeloid leukemia (64), and the role of the pathway in suppressing CTL activity in a murine leukemia model (65) also support exploration of PD-1 pathway-targeted agents in hematologic malignancies, and indeed, preliminary evidence of activity was observed with the IgG1 CT-011.

There are valid reasons to expect that differences will emerge in activity or toxicity of the different PD-1/B7-H1 antagonists, because of differences in binding affinity, target, or antibody isotype. Antibody isotype can influence the ability to mediate antibody- and/or complement-dependent cell-mediated cytotoxicity [antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cellular cytotoxicity (CDCC)]. An IgG1 anti-PD-1 antibody that mediates strong ADCC or CDCC could result in the death of PD-1–expressing T cells, thus eliminating the cell population responsible for mediating antitumor effects. Conversely, ADCC and CDCC by an anti-PD-1 might be advantageous in eliminating intratumoral Treg or malignant hematopoietic cells expressing PD-1, and could also be desirable functions in anti-B7-H1 antibodies, by predominantly targeting cancer cells (although T cells can also express B7-H1). Human IgG4 isotype antibodies have a reduced capacity to mediate ADCC and CDCC in comparison with IgG1 isotype antibodies. Agents with lower binding affinity to the target may affect the adequacy or duration of pathway blockade and blocking PD-1 versus B7-H1 may lead to differing outcomes because of other unblocked coreceptor interactions in this pathway as discussed previously. Predicted differences in potential toxicity profiles (i.e., lower pulmonary toxicity) by blocking B7-H1 versus PD-1 because of unblocked expression of B7-DC in lung have not been verified yet in clinical trials. Additional data, including possibly head-to-head trials, will be required.

The key challenge for further clinical development of PD-1 pathway blockade is to understand the tumor–host immune relationship(s) which is/are permissive for clinical activity without other interventions, and the tumor–host immune relationships which require other therapeutic interventions in addition to PD-1 pathway blockade to produce optimal antitumor effects. A recent study showed that B7-H1 was expressed on a proportion (57 of 150) of various melanocytic lesions including primary, mMEL, and various types of nevi, most commonly only at the edges of the tumor bed or in opposition to TILs (47). Four distinct groups of tumors were identified and described as having the presence of both B7-H1 and TILs, presence of TILs without B7-H1, B7-H1 expression without TILs, or absence of both TILs and B7-H1 expression (Fig. 3). As analyzed by laser-capture microdissection of the tumor edge, selective expression of IFN-γ mRNA, a potent inducer of membrane B7-H1, was shown to correlate with tumor B7-H1 expression. These data suggest that a subset of patients have an ongoing immune response within the tumor microenvironment and that B7-H1 expression is an adaptive method of tumor resistance to cytokine-producing TILs. Another patient subset likely upregulates B7-H1 expression through aberrant cell signaling, for example, via PTEN loss (66) or via activation of the MEK/ERK or MyD88 signaling pathways, which participate in the upregulation of B7-H1 in response to IFN-γ or Toll-like receptor signaling (67–69). The data also raise important questions about the function and specificity of TIL in B7-H1− tumors and the biologic basis for tumors lacking TIL. In the latter group, it is appropriate to ask whether the lack of T-cell infiltration reflects the absence of tumor antigen-specific responses or an as-yet unidentified process that excludes TIL from the microenvironment.

Figure 3.
Figure 3.

B7-H1 expression and inflammation: implications for mechanisms and therapy. I, B7-H1− tumor without TILs. II, B7-H1+ melanoma with TILs at advancing edge. III, B7-H1− tumor with TILs present. IV, B7-H1+ tumor without TILs. Panel IV reprinted with permission from ref. 47.

The findings in the study by Taube and colleagues may have important implications for B7-H1 as a prognostic and predictive biomarker as well as a target for therapy. The subgroup with both B7-H1 expression and TILs may have improved prognosis compared with the group with B7-H1 expression without TILs; indeed, multiple literature studies have shown improved prognosis associated with the presence of TIL (70, 71). Consistent with this hypothesis, patients with B7-H1+ mMEL, which is more commonly associated with TIL, had significantly longer survival than those with B7-H1− mMEL (P = 0.032; ref. 47). Current data also raise concern for using tumor B7-H1 expression as a predictive biomarker to select individual patients for treatment with PD-1/B7-H1 blockade or to select certain tumor types for development. Designation of positive B7-H1 expression remains confounded by tumor heterogeneity, variability in the assays, location of intratumoral expression, and clear cutoff values for positive versus negative expression. Moreover, the association of TIL with B7-H1 expression, or perhaps simply the presence of TIL, may be more important for predicting response than B7-H1 expression alone. Intriguingly, immune cells that infiltrate colorectal cancer have been observed to organize into intratumoral structures, which resemble lymph nodes; this associates with a particular chemokine signature, which may be useful in identifying immunotherapy-responsive patients, especially if similar phenomena are observed in other tumor types (72). The association of intratumoral lymphocytes and chemokine expression with TIL PD-1 expression and/or tumor B7-H1 expression has not yet been defined. Ascierto and colleagues discuss biomarkers for immunostimulatory antibody therapy in this issue of Clinical Cancer Research (73).

Substantial therapeutic advances for the B7-H1+ TIL+ subgroup may follow further characterization of other coinhibitory ligand–receptor interactions or immune suppressive factors in the tumor microenvironment. Recent murine studies suggest that concurrent blockade of other exhaustion/coinhibitory molecules (TIM3 and LAG3) and PD-1 can result in synergistic antitumor activity, and 1 preclinical study suggested incremental activity by blocking both PD-1 and B7-H1 (74–76). TIL and/or peripheral blood lymphocyte CTLA-4 expression increases in response to PD-1 blockade in both animal tumors and in patients, and assuming that CTLA-4 ligands are present in the tumor microenvironment, these data provide a rationale for the ongoing phase I trial of anti-PD-1 and anti-CTLA-4 (J. Weber, personal communication). For noninflamed tumors, strategies that induce and expand tumor-antigen–specific T cells and drive them into the tumor microenvironment may be necessary before or concurrent with PD-1 pathway blockade. Potential strategies to drive T cells into the tumor microenvironment include anti-CTLA-4, IFNs (which also induce surface B7-H1 expression), and signaling antagonists such as B-raf inhibitors (e.g., vemurafenib; refs. 71, 77, 78). Compared with pretreatment tumor biopsies, TIL populations (especially CD8+ T cells) increased in biopsies taken after patients with mMEL were treated with vemurafenib or dabrafenib, suggesting that the combination of B-raf inhibitors and immunotherapies such as PD-1-pathway inhibitors might complement one another and lead to improved patient outcomes (78). As mentioned earlier, preclinical studies have also supported combinations of anti-PD-1 antibodies with a variety of agents including chemotherapy, cytokines, and costimulatory agents such as anti-CD137 (32); CD40 is another promising immunostimulatory target (79). Although combinations with chemotherapy will be preferred in diseases where chemotherapy is standard of care, it will also be important to assess the activity of PD-1 blockade alone and in combination with other immune therapies. If additional data confirm that tumor B7-H1 expression at a predefined level is a predictive biomarker for activity of PD-1 blockade alone, the lack of expression should not preclude testing combinations of PD-1 with other agents that could drive T cells into the tumor microenvironment. Finally, combinations of PD-1 blockade with other agents such as anti-CTLA-4 antibodies would be predicted to produce greater levels of immune-related adverse events. In the setting of potentially increased activity of such combinations, the observation of unique and increased toxicities should not preclude continued development, because of the capacity to develop effective management algorithms as already shown in clinical studies of anti-CTLA-4 antibodies.

Disclosure of Potential Conflicts of Interest

M. Sznol is a consultant/advisory board member of Bristol-Myers Squibb. L. Chen has a commercial research grant from Amplimmune Inc. and is a consultant/advisory board member of Amplimmune.

Authors' Contributions

Conception and design: M. Sznol, L. Chen

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): M. Sznol, L. Chen

Writing, review, and/or revision of the manuscript: M. Sznol, L. Chen

Grant Support

This study is partially supported by Melanoma Research Alliance and NIH grants CA142779 and CA121974.

Acknowledgments

The authors thank Cailin Moira Wilke, PhD (StemScientific, funded by Bristol-Myers Squibb) for professional medical writing and editorial assistance.

  • Received October 16, 2012.
  • Revision received December 19, 2012.
  • Accepted January 10, 2013.

References

  1. 1.↵
    1. Ishida Y,
    2. Agata Y,
    3. Shibahara K,
    4. Honjo T
    . Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 1992;11:3887–95.
    OpenUrlPubMed
  2. 2.↵
    1. Chen L
    . Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 2004;4:336–47.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Keir ME,
    2. Liang SC,
    3. Guleria I,
    4. Latchman YE,
    5. Qipo A,
    6. Albacker LA,
    7. et al.
    Tissue expression of B7-H1 mediates peripheral T cell tolerance. J Exp Med 2006;203:883–95.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Keir ME,
    2. Butte MJ,
    3. Freeman GJ,
    4. Sharpe AH
    . PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008;26:677–704.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Dong H,
    2. Zhu G,
    3. Tamada K,
    4. Chen L
    . B7-H1, a third member of the B7 family, costimulates T-cell proliferation and interleukin-10 secretion. Nat Med 1999;5:1365–9.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Latchman Y,
    2. Wood CR,
    3. Chernova T,
    4. Chaudhary D,
    5. Borde M,
    6. Chernova I,
    7. et al.
    PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2001;2:261–8.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Zou W,
    2. Chen L
    . Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 2008;8:467–77.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Rozali EN,
    2. Hato SV,
    3. Robinson BW,
    4. Lake RA,
    5. Lesterhuis WJ
    . Programmed death ligand 2 in cancer-induced immune suppression. Clin Dev Immunol 2012:656340.
  9. 9.↵
    1. Dong H,
    2. Strome SE,
    3. Salomao DR,
    4. Tamura H,
    5. Hirano F,
    6. Flies DB,
    7. et al.
    Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002;8:793–800.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Eppihimer MJ,
    2. Gunn J,
    3. Freeman GJ,
    4. Greenfield EA,
    5. Chernova T,
    6. Erickson J,
    7. et al.
    Expression and regulation of the B7-H1 immunoinhibitory molecule on microvascular endothelial cells. Microcirculation 2002;9:133–45.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Yamazaki T,
    2. Akiba H,
    3. Iwai H,
    4. Matsuda H,
    5. Aoki M,
    6. Tanno Y,
    7. et al.
    Expression of programmed death 1 ligands by murine T cells and APC. J Immunol 2002;169:5538–45.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Curiel TJ,
    2. Wei S,
    3. Dong H,
    4. Alvarez X,
    5. Cheng P,
    6. Mottram P,
    7. et al.
    Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med 2003;9:562–7.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Brown JA,
    2. Dorfman DM,
    3. Ma FR,
    4. Sullivan EL,
    5. Munoz O,
    6. Wood CR,
    7. et al.
    Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol 2003;170:1257–66.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Rodig N,
    2. Ryan T,
    3. Allen JA,
    4. Pang H,
    5. Grabie N,
    6. Chernova T,
    7. et al.
    Endothelial expression of PD-L1 and PD-L2 down-regulates CD8+ T-cell activation and cytolysis. Eur J Immunol 2003;33:3117–26.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Messal N,
    2. Serriari NE,
    3. Pastor S,
    4. Nunès JA,
    5. Olive D
    . PD-L2 is expressed on activated human T cells and regulates their function. Mol Immunol 2011;48:2214–9.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Shin T,
    2. Kennedy G,
    3. Gorski K,
    4. Tsuchiya H,
    5. Koseki H,
    6. Azuma M,
    7. et al.
    Cooperative B7-1/2 (CD80/CD86) and B7-DC costimulation of CD4+ T cells independent of the PD-1 receptor. J Exp Med 2003;198:31–8.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    1. Ishiwata K,
    2. Watanabe N,
    3. Guo M,
    4. Tomihara K,
    5. Brumlik MJ,
    6. Yagita H,
    7. et al.
    Costimulator B7-DC attenuates strong Th2 responses induced by Nippostrongylus brasiliensis . J Immunol 2010;184:2086–94.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Yokosuka T,
    2. Takamatsu M,
    3. Kobayashi-Imanishi W,
    4. Hashimoto-Tane A,
    5. Azuma M,
    6. Saito T
    . Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. J Exp Med 2012;209:1201–17.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Patsoukis N,
    2. Sari D,
    3. Boussiotis VA
    . PD-1 inhibits T cell proliferation by upregulating p27 and p15 and suppressing Cdc25A. Cell Cycle 2012;11:4305–9.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Dong H,
    2. Strome SE,
    3. Matteson EL,
    4. Moder KG,
    5. Flies DB,
    6. Zhu G,
    7. et al.
    Costimulating aberrant T cell responses by B7-H1 autoantibodies in rheumatoid arthritis. J Clin Invest 2003;111:363–70.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Kuipers H,
    2. Muskens F,
    3. Willart M,
    4. Hijdra D,
    5. van Assema FB,
    6. Coyle AJ,
    7. et al.
    Contribution of the PD-1 ligands/PD-1 signaling pathway to dendritic cell-mediated CD4+ T cell activation. Eur J Immunol 2006;36:2472–82.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Azuma T,
    2. Yao S,
    3. Zhu G,
    4. Flies AS,
    5. Flies SJ,
    6. Chen L
    . B7-1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood 2008;111:3635–43.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    1. Mueller SN,
    2. Vanguri VK,
    3. Ha SJ,
    4. West EE,
    5. Keir ME,
    6. Glickman JN,
    7. et al.
    PD-L1 has distinct functions in hematopoietic and nonhematopoietic cells in regulating T cell responses during chronic infection in mice. J Clin Invest 2010;120:2508–15.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Goldberg MV,
    2. Maris CH,
    3. Hipkiss EL,
    4. Flies AS,
    5. Zhen L,
    6. Tuder RM,
    7. et al.
    Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells. Blood 2007;110:186–92.
    OpenUrlAbstract/FREE Full Text
  25. 25.↵
    1. Nishimura H,
    2. Nose M,
    3. Hiai H,
    4. Minato N,
    5. Honjo T
    . Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999;11:141–5.
    OpenUrlCrossRefPubMed
  26. 26.↵
    1. Nishimura H,
    2. Okazaki T,
    3. Tanaka Y,
    4. Nakatani K,
    5. Hara M,
    6. Matsumori A,
    7. et al.
    Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 2001;291:319–22.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    1. Dong H,
    2. Zhu G,
    3. Tamada K,
    4. Flies DB,
    5. van Deursen JM,
    6. Chen L
    . B7-H1 determines accumulation and deletion of intrahepatic CD8(+) T lymphocytes. Immunity 2004;20:327–36.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Ni L,
    2. Ma CJ,
    3. Zhang Y,
    4. Nandakumar S,
    5. Zhang CL,
    6. Wu XY,
    7. et al.
    PD-1 modulates regulatory T cells and suppresses T-cell responses in HCV-associated lymphoma. Immunol Cell Biol 2011;89:535–9.
    OpenUrlCrossRefPubMed
  29. 29.↵
    1. Francisco LM,
    2. Salinas VH,
    3. Brown KE,
    4. Vanguri VK,
    5. Freeman GJ,
    6. Kuchroo VK,
    7. et al.
    PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med 2009;206:3015–29.
    OpenUrlAbstract/FREE Full Text
  30. 30.↵
    1. Iwai Y,
    2. Terawaki S,
    3. Honjo T
    . PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. Int Immunol 2005;17:133–44.
    OpenUrlAbstract/FREE Full Text
  31. 31.↵
    1. Okudaira K,
    2. Hokari R,
    3. Tsuzuki Y,
    4. Okada Y,
    5. Komoto S,
    6. Watanabe C,
    7. et al.
    Blockade of B7-H1 or B7-DC induces an anti-tumor effect in a mouse pancreatic cancer model. Int J Oncol 2009;35:741–9.
    OpenUrlPubMed
  32. 32.↵
    1. Hirano F,
    2. Kaneko K,
    3. Tamura H,
    4. Dong H,
    5. Wang S,
    6. Ichikawa M,
    7. et al.
    Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res 2005;65:1089–96.
    OpenUrlAbstract/FREE Full Text
  33. 33.↵
    1. Webster WS,
    2. Thompson RH,
    3. Harris KJ,
    4. Frigola X,
    5. Kuntz S,
    6. Inman BA,
    7. et al.
    Targeting molecular and cellular inhibitory mechanisms for improvement of antitumor memory responses reactivated by tumor cell vaccine. J Immunol 2007;179:2860–9.
    OpenUrlAbstract/FREE Full Text
  34. 34.↵
    1. Li B,
    2. VanRoey M,
    3. Wang C,
    4. Chen TH,
    5. Korman A,
    6. Jooss K
    . Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor–secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors. Clin Cancer Res 2009;15:1623–34.
    OpenUrlAbstract/FREE Full Text
  35. 35.↵
    1. Mangsbo SM,
    2. Sandin LC,
    3. Anger K,
    4. Korman AJ,
    5. Loskog A,
    6. Tötterman TH
    . Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy. J Immunother 2010;33:225–35.
    OpenUrlCrossRef
  36. 36.↵
    1. Zhou Q,
    2. Xiao H,
    3. Liu Y,
    4. Peng Y,
    5. Hong Y,
    6. Yagita H,
    7. et al.
    Blockade of programmed death-1 pathway rescues the effector function of tumor-infiltrating T cells and enhances the antitumor efficacy of lentivector immunization. J Immunol 2010;185:5082–92.
    OpenUrlAbstract/FREE Full Text
  37. 37.↵
    1. Mkrtichyan M,
    2. Najjar YG,
    3. Raulfs EC,
    4. Abdalla MY,
    5. Samara R,
    6. Rotem-Yehudar R,
    7. et al.
    Anti-PD-1 synergizes with cyclophosphamide to induce potent anti-tumor vaccine effects through novel mechanisms. Eur J Immunol 2011;41:2977–86.
    OpenUrlCrossRefPubMed
  38. 38.↵
    1. Wherry EJ
    . T-cell exhaustion. Nat Immunol 2011;12:492–9.
    OpenUrlCrossRefPubMed
  39. 39.↵
    1. Gros A,
    2. Turcotte S,
    3. Tran E,
    4. Hanada K,
    5. Wunderlich JR,
    6. Rosenberg S
    . Selection of PD-1, LAG-3, TIM-3 and 41BB positive CD8 T cells in the fresh tumor digest enriches for melanoma-reactive cells. J Immunother 2012;35:722.
    OpenUrl
  40. 40.↵
    1. Melero I,
    2. Hirschhorn-Cymerman D,
    3. Morales-Kastresana A,
    4. Sanmamed MF,
    5. Wolchok JD
    . Agonist antibodies to TNFR molecules that costimulate T and NK cells. Clin Cancer Res 2013;19:1044–53.
    OpenUrlAbstract/FREE Full Text
  41. 41.↵
    1. Mkrtichyan M,
    2. Najjar YG,
    3. Raulfs EC,
    4. Liu L,
    5. Langerman S,
    6. Guittard G,
    7. et al.
    B7-DC-Ig enhances vaccine effect by a novel mechanism dependent on PD-1 expression level on T cell subsets. J Immunol 2012;189:2338–47.
    OpenUrlAbstract/FREE Full Text
  42. 42.↵
    1. Ahmadzadeh M,
    2. Johnson LA,
    3. Heemskerk B,
    4. Wunderlich JR,
    5. Dudley ME,
    6. White DE,
    7. et al.
    Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009;114:1537–44.
    OpenUrlAbstract/FREE Full Text
  43. 43.↵
    1. Kinter AL,
    2. Godbout EJ,
    3. McNally JP,
    4. Sereti I,
    5. Roby GA,
    6. O'Shea MA,
    7. et al.
    The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands. J Immunol 2008;181:6738–46.
    OpenUrlAbstract/FREE Full Text
  44. 44.↵
    1. Karim R,
    2. Jordanova ES,
    3. Piersma SJ,
    4. Kenter GG,
    5. Chen L,
    6. Boer JM,
    7. et al.
    Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma. Clin Cancer Res 2009;15:6341–7.
    OpenUrlAbstract/FREE Full Text
  45. 45.↵
    1. Konishi J,
    2. Yamazaki K,
    3. Azuma M,
    4. Kinoshita I,
    5. Dosaka-Akita H,
    6. Nishimura M
    . B7-H1 expression on non small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res 2004;10:5094–100.
    OpenUrlAbstract/FREE Full Text
  46. 46.↵
    1. Mischinger J,
    2. Froehlich E,
    3. Griesbacher A,
    4. Pummer K,
    5. Mannweiler S,
    6. Zigeuner R,
    7. et al.
    Prognostic relevance of B7H1 and B7H3 protein expressions in metastatic clear cell renal cell carcinoma. J Clin Oncol 28, 2010 (suppl; abstr e15074).
  47. 47.↵
    1. Taube JM,
    2. Anders RA,
    3. Young GD,
    4. Xu H,
    5. Sharma R,
    6. McMiller TL,
    7. et al.
    Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012;4:127ra37.
    OpenUrlAbstract/FREE Full Text
  48. 48.↵
    1. Thompson RH,
    2. Kuntz SM,
    3. Leibovich BC,
    4. Dong H,
    5. Lohse CM,
    6. Webster WS,
    7. et al.
    Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 2006;66:3381–5.
    OpenUrlAbstract/FREE Full Text
  49. 49.↵
    1. Ohigashi Y,
    2. Sho M,
    3. Yamada Y,
    4. Tsurui Y,
    5. Hamada K,
    6. Ikeda N,
    7. et al.
    Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res 2005;11:2947–53.
    OpenUrlAbstract/FREE Full Text
  50. 50.↵
    1. Nomi T,
    2. Sho M,
    3. Akahori T,
    4. Hamada K,
    5. Kubo A,
    6. Kanehiro H,
    7. et al.
    Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res 2007;13:2151–7.
    OpenUrlAbstract/FREE Full Text
  51. 51.↵
    1. Gao Q,
    2. Wang XY,
    3. Qiu SJ,
    4. Yamato I,
    5. Sho M,
    6. Nakajima Y,
    7. et al.
    Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res 2009;15:971–9.
    OpenUrlAbstract/FREE Full Text
  52. 52.↵
    1. Hamanishi J,
    2. Mandai M,
    3. Abiko K,
    4. Matsumura N,
    5. Baba T,
    6. Yoshioka Y,
    7. et al.
    The comprehensive assessment of local immune status of ovarian cancer by the clustering of multiple immune factors. Clin Immunol 2011;141:338–47.
    OpenUrlCrossRefPubMed
  53. 53.↵
    1. Blank C,
    2. Kuball J,
    3. Voelkl S,
    4. Wiendl H,
    5. Becker B,
    6. Walter B,
    7. et al.
    Blockade of B7-H1 (B7-H1) augments human tumor-specific T cell responses in vitro . Int J Cancer 2006;119:317–27.
    OpenUrlCrossRefPubMed
  54. 54.↵
    1. Wong RM,
    2. Scotland RR,
    3. Lau RL,
    4. Wang C,
    5. Korman AJ,
    6. Kast WM,
    7. et al.
    Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs. Int Immunol 2007;19:1223–34.
    OpenUrlAbstract/FREE Full Text
  55. 55.↵
    1. Zhang Y,
    2. Huang S,
    3. Gong D,
    4. Qin Y,
    5. Shen Q
    . Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non–small cell lung cancer. Cell Mol Immunol 2010;7:389–95.
    OpenUrlCrossRefPubMed
  56. 56.↵
    1. Brahmer JR,
    2. Drake CG,
    3. Wollner I,
    4. Powderly JD,
    5. Picus J,
    6. Sharfman WH,
    7. et al.
    Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010;28:3167–75.
    OpenUrlAbstract/FREE Full Text
  57. 57.↵
    1. Topalian SL,
    2. Hodi FS,
    3. Brahmer JR,
    4. Gettinger SN,
    5. Smith DC,
    6. McDermott DF,
    7. et al.
    Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443–54.
    OpenUrlCrossRefPubMed
  58. 58.↵
    1. Topalian SL,
    2. Brahmer JR,
    3. Hodi FS,
    4. McDermott DF,
    5. Smith DC,
    6. Gettinger S,
    7. et al.
    Anti-PD-1 (BMS-936558/MDX-1106/ONO-4538) in patients with advanced solid tumors: clinical activity, safety, and molecular markers. Poster presentation European Society for Medical Oncology; 2012.
  59. 59.↵
    1. Patnaik A,
    2. Kang SP,
    3. Tolcher AW,
    4. Rasco DW,
    5. Papadopoulos KP,
    6. Beeram M,
    7. et al.
    Phase I study of MK-3475 (anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. J Clin Oncol 30, 2012 (suppl; abstr 2512).
  60. 60.↵
    1. Hamid O,
    2. Daud A,
    3. Robert C,
    4. et al.
    Preliminary clinical efficacy and safety of MK-3475 (anti-PD-1 monoclonal antibody) in patients with advanced melanoma. Presented at Society for Melanoma Research; 2012 Nov 11; Hollywood, CA.
  61. 61.↵
    1. Berger R,
    2. Rotem-Yehudar R,
    3. Slama G,
    4. Landes S,
    5. Kneller A,
    6. Leiba M,
    7. et al.
    Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res 2008;14:3044–51.
    OpenUrlAbstract/FREE Full Text
  62. 62.↵
    1. Brahmer JR,
    2. Tykodi SS,
    3. Chow LQ,
    4. Hwu WJ,
    5. Topalian SL,
    6. Hwu P,
    7. et al.
    Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455–65.
    OpenUrlCrossRefPubMed
  63. 63.↵
    MedImmune joins forces with leading cancer organizations to advance novel immunotherapy research [press release] . Gaithersburg, MD: MedImmune, LLC; October 9, 2012.
  64. 64.↵
    1. Matte-Martone C,
    2. Venkatesan S,
    3. Tan HS,
    4. Athanasiadis I,
    5. Chang J,
    6. Pavisic J,
    7. et al.
    Graft-versus-leukemia (GVL) against mouse blast-crisis chronic myelogenous leukemia (BC-CML) and chronic-phase chronic myelogenous leukemia (CP-CML): shared mechanisms of T cell killing, but programmed death ligands render CP-CML and not BC-CML GVL resistant. J Immunol 2011;187:1653–63.
    OpenUrlAbstract/FREE Full Text
  65. 65.↵
    1. Zhou Q,
    2. Munger ME,
    3. Highfill SL,
    4. Tolar J,
    5. Weigel BJ,
    6. Riddle M,
    7. et al.
    Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia. Blood 2010;116:2484–93.
    OpenUrlAbstract/FREE Full Text
  66. 66.↵
    1. Parsa AT,
    2. Waldron JS,
    3. Panner A,
    4. Crane CA,
    5. Parney IF,
    6. Barry JJ,
    7. et al.
    Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med 2007;13:84–8.
    OpenUrlCrossRefPubMed
  67. 67.↵
    1. Liu J,
    2. Hamrouni A,
    3. Wolowiec D,
    4. Coiteux V,
    5. Kuliczkowski K,
    6. Hetuin D,
    7. et al.
    Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood 2007;110:296–304.
    OpenUrlAbstract/FREE Full Text
  68. 68.↵
    1. De Luca A,
    2. Maiello MR,
    3. D'Alessio A,
    4. Pergameno M,
    5. Normanno N
    . The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Ther Targets 2012;16(Suppl 2):S17–27.
    OpenUrlCrossRef
  69. 69.↵
    1. Coste I,
    2. Le Corf K,
    3. Kfoury A,
    4. Hmitou I,
    5. Druillennec S,
    6. Hainaut P,
    7. et al.
    Dual function of MyD88 in RAS signaling and inflammation, leading to mouse and human cell transformation. J Clin Invest 2010;120:3663–7.
    OpenUrlCrossRefPubMed
  70. 70.↵
    1. Pagès F,
    2. Berger A,
    3. Camus M,
    4. Sanchez-Cabo F,
    5. Costes A,
    6. Molidor R,
    7. et al.
    Effector memory T-cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005;353:2654–66.
    OpenUrlCrossRefPubMed
  71. 71.↵
    1. Hamid O,
    2. Schmidt H,
    3. Nissan A,
    4. Ridolfi L,
    5. Aamdal S,
    6. Hansson J,
    7. et al.
    A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med 2011;9:204.
    OpenUrlCrossRefPubMed
  72. 72.↵
    1. Coppola D,
    2. Nebozhyn M,
    3. Khalil F,
    4. Dai H,
    5. Yeatman T,
    6. Loboda A,
    7. et al.
    Unique ectopic lymph node-like structures present in human primary colorectal carcinoma are identified by immune gene array profiling. Am J Pathol 2011;179:37–45.
    OpenUrlCrossRefPubMed
  73. 73.↵
    1. Ascierto PA,
    2. Kalos M,
    3. Schaer DA,
    4. Callahan MK,
    5. Wolchok JD
    . Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types. Clin Cancer Res 2013;19:1009–20.
    OpenUrlAbstract/FREE Full Text
  74. 74.↵
    1. Curran MA,
    2. Montalvo W,
    3. Yagita H,
    4. Allison JP
    . PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A 2010;107:4275–80.
    OpenUrlAbstract/FREE Full Text
  75. 75.↵
    1. Ngiow SF,
    2. von Scheidt B,
    3. Akiba H,
    4. Yagita H,
    5. Teng MW,
    6. Smyth MJ
    . Anti-TIM3 antibody promotes T cell IFN-γ-mediated antitumor immunity and suppresses established tumors. Cancer Res 2011;71:3540–51.
    OpenUrlAbstract/FREE Full Text
  76. 76.↵
    1. Woo SR,
    2. Turnis ME,
    3. Goldberg MV,
    4. Bankoti J,
    5. Selby M,
    6. Nirschl CJ,
    7. et al.
    Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res 2012;72:917–27.
    OpenUrlAbstract/FREE Full Text
  77. 77.↵
    1. Onishi T,
    2. Machida T,
    3. Masuda F,
    4. Hatano T,
    5. Shirakawa H,
    6. Natori T,
    7. et al.
    Assessment of tumour-infiltrating lymphocytes, regional lymph node lymphocytes and peripheral blood lymphocytes and their reaction to interferon-gamma in patients with renal carcinoma. Br J Urol 1991;67:459–66.
    OpenUrlCrossRefPubMed
  78. 78.↵
    1. Wilmott JS,
    2. Long GV,
    3. Howle JR,
    4. Haydu LE,
    5. Sharma RN,
    6. Thompson JF,
    7. et al.
    Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res 2012;18:1386–94.
    OpenUrlAbstract/FREE Full Text
  79. 79.↵
    1. Vonderheide RH,
    2. Glennie MJ
    . Agonistic CD40 antibodies and cancer therapy. Clin Cancer Res 2013;19:1035–43.
    OpenUrlAbstract/FREE Full Text
  80. 80.
    1. Jacobs JF,
    2. Idema AJ,
    3. Bol KF,
    4. Nierkens S,
    5. Grauer OM,
    6. Wesseling P,
    7. et al.
    Regulatory T cells and the B7-H1/PD-1 pathway mediate immune suppression in malignant human brain tumors. Neuro Oncol 2009;11:394–402.
    OpenUrlAbstract/FREE Full Text
  81. 81.
    1. Nakanishi J,
    2. Wada Y,
    3. Matsumoto K,
    4. Azuma M,
    5. Kikuchi K,
    6. Ueda S
    . Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. Cancer Immunol Immunother 2007;56:1173–82.
    OpenUrlCrossRefPubMed
  82. 82.
    1. Wu C,
    2. Zhu Y,
    3. Jiang J,
    4. Zhao J,
    5. Zhang XG,
    6. Xu N
    . Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta Histochem 2006;108:19–24.
    OpenUrlCrossRefPubMed
  83. 83.
    1. Mu CY,
    2. Huang JA,
    3. Chen Y,
    4. Chen C,
    5. Zhang XG
    . High expression of B7-H1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol 2011;28:682–8.
    OpenUrlCrossRefPubMed
  84. 84.
    1. Wintterle S,
    2. Schreiner B,
    3. Mitsdoerffer M,
    4. Schneider D,
    5. Chen L,
    6. Meyermann R,
    7. et al.
    Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. Cancer Res 2003;63:7462–7.
    OpenUrlAbstract/FREE Full Text
  85. 85.
    1. Wang BJ,
    2. Bao JJ,
    3. Wang JZ,
    4. Wang Y,
    5. Jiang M,
    6. Xing MY,
    7. et al.
    Immunostaining of PD-1/PD-Ls in liver tissues of patients with hepatitis and hepatocellular carcinoma. World J Gastroenterol 2011;17:3322–9.
    OpenUrlCrossRefPubMed
  86. 86.
    1. Shi F,
    2. Shi M,
    3. Zeng Z,
    4. Qi RZ,
    5. Liu ZW,
    6. Zhang JY,
    7. et al.
    PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. Int J Cancer 2011;128:887–96.
    OpenUrlCrossRefPubMed
  87. 87.
    1. Hino R,
    2. Kabashima K,
    3. Kato Y,
    4. Yagi H,
    5. Nakamura M,
    6. Honjo T,
    7. et al.
    Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer 2010;116:1757–66.
    OpenUrlCrossRefPubMed
  88. 88.
    1. Chapon M,
    2. Randriamampita C,
    3. Maubec E,
    4. Badoual C,
    5. Fouquet S,
    6. Wang SF,
    7. et al.
    Progressive upregulation of PD-1 in primary and metastatic melanomas associated with blunted TCR signaling in infiltrating T lymphocytes. J Invest Dermatol 2011;131:1300–7.
    OpenUrlCrossRefPubMed
  89. 89.
    1. Strome SE,
    2. Dong H,
    3. Tamura H,
    4. Voss SG,
    5. Flies DB,
    6. Tamada K,
    7. et al.
    B7-H1 blockade augments adoptiveT-cell immunotherapy for squamous cell carcinoma. Cancer Res 2003;63:6501–5.
    OpenUrlAbstract/FREE Full Text
  90. 90.
    1. Lyford-Pike S,
    2. Peng S,
    3. Taube JM,
    4. Westra WH,
    5. Akpeng B,
    6. Wang H,
    7. et al.
    PD-1:B7-H1(B7-H1) pathway in adaptive resistance: a novel mechanism for tumor immune escape in human papillomavirus-related head and neck cancers. J Clin Oncol 30, 2012 (suppl; abstr 5506).
  91. 91.
    1. Salih HR,
    2. Wintterle S,
    3. Krusch M,
    4. Kroner A,
    5. Huang YH,
    6. Chen L,
    7. et al.
    The role of leukemia-derived B7-H1 (PD-L1) in tumor-T-cell interactions in humans. Exp Hematol 2006;34:888–94.
    OpenUrlCrossRefPubMed
  92. 92.
    1. Sfanos KS,
    2. Bruno TC,
    3. Meeker AK,
    4. De Marzo AM,
    5. Isaacs WB,
    6. Drake CG
    . Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+ . Prostate 2009;69:1694–703.
    OpenUrlCrossRefPubMed
  93. 93.
    1. Ghebeh H,
    2. Mohammed S,
    3. Al-Omair A,
    4. Qattan A,
    5. Lehe C,
    6. Al-Qudaihi G,
    7. et al.
    The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia 2006;8:190–8.
    OpenUrlCrossRefPubMed
  94. 94.
    1. Inman BA,
    2. Sebo TJ,
    3. Frigola X,
    4. Dong H,
    5. Bergstralh EJ,
    6. Frank I,
    7. et al.
    PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. Cancer 2007;109:1499–505.
    OpenUrlCrossRefPubMed
Back to top
Clinical Cancer Research: 19 (5)
March 2013
Volume 19, Issue 5

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Email Article
Citation Tools
Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer
Mario Sznol and Lieping Chen
Clin Cancer Res March 1 2013 (19) (5) 1021-1034; DOI: 10.1158/1078-0432.CCR-12-2063
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Jump to section

Advertisement